Illinois-based AbbVie announced that the company will acquire Ireland-based Allergan for $63 billion in a cash and stock deal.
GlaxoSmithKline offered concessions to address EU antitrust concerns over the planned joint venture with Pfizer’s consumer health business, the European Commission said.
Vancouver-based AbCellera and Gilead Sciences forged a collaborative agreement to discover and develop ultra-rare antibodies that can be used in the treatment of a number of infectious diseases.
Stada said on Friday the private equity-backed company would buy six consumer healthcare products from British GlaxoSmithKline to bolster the generic drugmaker’s presence in Europe.
Vertex Pharmaceuticals will acquire privately held Exonics Therapeutics for an upfront payment of $245 million and potential milestone payments of up to $750 million.
German drugmaker Bayer signed an alliance with Arvinas Inc. to gain access to the U.S. biotech firm’s experimental protein drugs and crop protection technology in a deal worth up to $750 million.
Bayer struck a collaboration deal with Roche’s Foundation Medicine Inc. to develop test kits for genetic sequencing of tumor cells to identify cancer patients that benefit from Bayer’s Vitrakvi drug.
Verily announced a strategic collaboration deal with Novartis, Otsuka, Pfizer, Sanofi, and six major health systems.
GlaxoSmithKline’s deal to buy Pfizer’s consumer healthcare business will not lesson competition in Australia, the country’s anti-trust regulator said.
British drugmaker AstraZeneca Plc and French biopharmaceutical firm Transgene SA entered into an agreement to jointly develop five cancer-killing viral immunotherapies.
